240 related articles for article (PubMed ID: 19128971)
1. Discovery of 2-(alpha-methylbenzylamino) pyrazines as potent Type II inhibitors of FMS.
Burns CJ; Harte MF; Bu X; Fantino E; Giarrusso M; Joffe M; Kurek M; Legge FS; Razzino P; Su S; Treutlein H; Wan SS; Zeng J; Wilks AF
Bioorg Med Chem Lett; 2009 Feb; 19(4):1206-9. PubMed ID: 19128971
[TBL] [Abstract][Full Text] [Related]
2. Discovery of pyrazol-3-ylamino pyrazines as novel JAK2 inhibitors.
Ioannidis S; Lamb ML; Davies AM; Almeida L; Su M; Bebernitz G; Ye M; Bell K; Alimzhanov M; Zinda M
Bioorg Med Chem Lett; 2009 Dec; 19(23):6524-8. PubMed ID: 19857966
[TBL] [Abstract][Full Text] [Related]
3. Structure-based optimization of a potent class of arylamide FMS inhibitors.
Meegalla SK; Wall MJ; Chen J; Wilson KJ; Ballentine SK; Desjarlais RL; Schubert C; Crysler CS; Chen Y; Molloy CJ; Chaikin MA; Manthey CL; Player MR; Tomczuk BE; Illig CR
Bioorg Med Chem Lett; 2008 Jun; 18(12):3632-7. PubMed ID: 18495479
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel FMS kinase inhibitors as anti-inflammatory agents.
Illig CR; Chen J; Wall MJ; Wilson KJ; Ballentine SK; Rudolph MJ; DesJarlais RL; Chen Y; Schubert C; Petrounia I; Crysler CS; Molloy CJ; Chaikin MA; Manthey CL; Player MR; Tomczuk BE; Meegalla SK
Bioorg Med Chem Lett; 2008 Mar; 18(5):1642-8. PubMed ID: 18242992
[TBL] [Abstract][Full Text] [Related]
5. Design, parallel synthesis, and crystal structures of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complex.
Parlow JJ; Case BL; Dice TA; Fenton RL; Hayes MJ; Jones DE; Neumann WL; Wood RS; Lachance RM; Girard TJ; Nicholson NS; Clare M; Stegeman RA; Stevens AM; Stallings WC; Kurumbail RG; South MS
J Med Chem; 2003 Sep; 46(19):4050-62. PubMed ID: 12954058
[TBL] [Abstract][Full Text] [Related]
6. Reducing ion channel activity in a series of 4-heterocyclic arylamide FMS inhibitors.
Wilson KJ; Illig CR; Chen J; Wall MJ; Ballentine SK; DesJarlais RL; Chen Y; Schubert C; Donatelli R; Petrounia I; Crysler CS; Molloy CJ; Chaikin MA; Manthey CL; Player MR; Tomczuk BE; Meegalla SK
Bioorg Med Chem Lett; 2010 Jul; 20(13):3925-9. PubMed ID: 20570147
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of novel anilinoquinolines as c-fms inhibitors.
Smalley TL; Chamberlain SD; Mills WY; Musso DL; Randhawa SA; Ray JA; Samano V; Frick L
Bioorg Med Chem Lett; 2007 Nov; 17(22):6257-60. PubMed ID: 17870531
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel acetanilide derivatives as potent and selective beta3-adrenergic receptor agonists.
Maruyama T; Onda K; Hayakawa M; Matsui T; Takasu T; Ohta M
Eur J Med Chem; 2009 Jun; 44(6):2533-43. PubMed ID: 19232786
[TBL] [Abstract][Full Text] [Related]
9. beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.
Yang SM; Scannevin RH; Wang B; Burke SL; Wilson LJ; Karnachi P; Rhodes KJ; Lagu B; Murray WV
Bioorg Med Chem Lett; 2008 Feb; 18(3):1135-9. PubMed ID: 18086526
[TBL] [Abstract][Full Text] [Related]
10. Identification, synthesis and SAR of amino substituted pyrido[3,2b]pyrazinones as potent and selective PDE5 inhibitors.
Owen DR; Walker JK; Jon Jacobsen E; Freskos JN; Hughes RO; Brown DL; Bell AS; Brown DG; Phillips C; Mischke BV; Molyneaux JM; Fobian YM; Heasley SE; Moon JB; Stallings WC; Joseph Rogier D; Fox DN; Palmer MJ; Ringer T; Rodriquez-Lens M; Cubbage JW; Blevis-Bal RM; Benson AG; Acker BA; Maddux TM; Tollefson MB; Bond BR; Macinnes A; Yu Y
Bioorg Med Chem Lett; 2009 Aug; 19(15):4088-91. PubMed ID: 19540112
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors.
Illig CR; Manthey CL; Meegalla SK; Wall MJ; Chen J; Wilson KJ; DesJarlais RL; Ballentine SK; Schubert C; Crysler CS; Chen Y; Molloy CJ; Chaikin MA; Donatelli RR; Yurkow E; Zhou Z; Player MR; Tomczuk BE
Bioorg Med Chem Lett; 2013 Dec; 23(23):6363-9. PubMed ID: 24138939
[TBL] [Abstract][Full Text] [Related]
12. Discovery and SAR of para-alkylthiophenoxyacetic acids as potent and selective PPARdelta agonists.
Zhang R; Deangelis A; Wang A; Sieber-McMaster E; Li X; Russell R; Pelton P; Xu J; Zhu P; Zhou L; Demarest K; Murray WV; Kuo GH
Bioorg Med Chem Lett; 2009 Feb; 19(4):1101-4. PubMed ID: 19168353
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase.
Milkiewicz KL; Weinberg LR; Albom MS; Angeles TS; Cheng M; Ghose AK; Roemmele RC; Theroff JP; Underiner TL; Zificsak CA; Dorsey BD
Bioorg Med Chem; 2010 Jun; 18(12):4351-62. PubMed ID: 20483621
[TBL] [Abstract][Full Text] [Related]
14. beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.
Yang SM; Scannevin RH; Wang B; Burke SL; Huang Z; Karnachi P; Wilson LJ; Rhodes KJ; Lagu B; Murray WV
Bioorg Med Chem Lett; 2008 Feb; 18(3):1140-5. PubMed ID: 18083558
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a new potent bisamide FMS kinase inhibitor.
El-Gamal MI; Jung MH; Oh CH
Bioorg Med Chem Lett; 2010 Jun; 20(11):3216-8. PubMed ID: 20457522
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and structure-activity relationship of imidazo(1,2-a)thieno(3,2-e)pyrazines as IKK-beta inhibitors.
Belema M; Bunker A; Nguyen VN; Beaulieu F; Ouellet C; Qiu Y; Zhang Y; Martel A; Burke JR; McIntyre KW; Pattoli MA; Daloisio C; Gillooly KM; Clarke WJ; Brassil PJ; Zusi FC; Vyas DM
Bioorg Med Chem Lett; 2007 Aug; 17(15):4284-9. PubMed ID: 17540562
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and structure-activity relationships of novel 2-substituted pyrazinoylguanidine epithelial sodium channel blockers: drugs for cystic fibrosis and chronic bronchitis.
Hirsh AJ; Molino BF; Zhang J; Astakhova N; Geiss WB; Sargent BJ; Swenson BD; Usyatinsky A; Wyle MJ; Boucher RC; Smith RT; Zamurs A; Johnson MR
J Med Chem; 2006 Jul; 49(14):4098-115. PubMed ID: 16821771
[TBL] [Abstract][Full Text] [Related]
18. Enantiomerically pure hexahydropyrazinoquinolines as potent and selective dopamine 3 subtype receptor ligands.
Ding K; Chen J; Ji M; Wu X; Varady J; Yang CY; Lu Y; Deschamps JR; Levant B; Wang S
J Med Chem; 2005 May; 48(9):3171-81. PubMed ID: 15857123
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of novel 3,4,6-substituted 2-quinolones as FMS kinase inhibitors.
Wall MJ; Chen J; Meegalla S; Ballentine SK; Wilson KJ; DesJarlais RL; Schubert C; Chaikin MA; Crysler C; Petrounia IP; Donatelli RR; Yurkow EJ; Boczon L; Mazzulla M; Player MR; Patch RJ; Manthey CL; Molloy C; Tomczuk B; Illig CR
Bioorg Med Chem Lett; 2008 Mar; 18(6):2097-102. PubMed ID: 18289848
[TBL] [Abstract][Full Text] [Related]
20. N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrazino[1,2-a]pyrimidine-2-carboxamides a novel class of potent HIV-1 integrase inhibitors.
Petrocchi A; Jones P; Rowley M; Fiore F; Summa V
Bioorg Med Chem Lett; 2009 Aug; 19(15):4245-9. PubMed ID: 19523819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
